Showing results (271-280 of 296) with videos related to
Sort By:
Pageof 30
Neurology|November 3, 2017
Assessing association of comorbidities with treatment choice and persistence in MS: A real-life multicenter studyAlice Laroni, Alessio Signori, Giorgia T Maniscalco, et al.Neurology|December 21, 2022
Hematopoietic Stem Cell Transplantation in People With Active Secondary Progressive Multiple SclerosisGiacomo Boffa, Alessio Signori, Luca Massacesi, et al.Frontiers in Oncology|February 27, 2024
Time to strategy failure and treatment beyond progression in pretreated metastatic renal cell carcinoma patients receiving nivolumab: <i>post-hoc</i> analysis of the Meet-URO 15 studyVeronica Murianni, Alessio Signori, Sebastiano Buti, et al.Clinical Genitourinary Cancer|November 27, 2024
Prognostic Impact of IMDC Category Shift From Baseline to Nivolumab Initiation in Metastatic Renal Cell Carcinoma: A Sub-Analysis of the MEET-URO 15 StudyBrigida Anna Maiorano, Martina Catalano, Chiara Mercinelli, et al.Multiple Sclerosis (Houndmills, Basingstoke, England)|July 26, 2018
Determinants of therapy switch in multiple sclerosis treatment-naïve patients: A real-life studyFrancesco Saccà, Roberta Lanzillo, Alessio Signori, et al.Journal of Translational Medicine|September 30, 2022
The prognostic value of the previous nephrectomy in pretreated metastatic renal cell carcinoma receiving immunotherapy: a sub-analysis of the Meet-URO 15 studySara Elena Rebuzzi, Alessio Signori, Giuseppe Luigi Banna, et al.Frontiers in Oncology|October 10, 2022
The prognostic value of baseline and early variations of peripheral blood inflammatory ratios and their cellular components in patients with metastatic renal cell carcinoma treated with nivolumab: The Δ-Meet-URO analysisSara Elena Rebuzzi, Alessio Signori, Marco Stellato, et al.Multiple Sclerosis and Related Disorders|March 26, 2020
First therapy choice in newly diagnosed Multiple Sclerosis patients: A multicenter Italian studyGiorgia T Maniscalco, Francesco Saccà, Roberta Lanzillo, et al.Journal of Neurology, Neurosurgery, and Psychiatry|September 28, 2022
Heterogeneity on long-term disability trajectories in patients with secondary progressive MS: a latent class analysis from Big MS Data networkAlessio Signori, Johannes Lorscheider, Sandra Vukusic, et al.Multiple Sclerosis (Houndmills, Basingstoke, England)|April 7, 2017
Long-term disability trajectories in primary progressive MS patients: A latent class growth analysisAlessio Signori, Guillermo Izquierdo, Alessandra Lugaresi, et al.Pageof 30